Re-imagining access to insulins
Our purpose at Sandoz is to pioneer novel ways to help people access high-quality medicines. In 2015, our products reached and estimated 520 million patients and our goal is to reach 1 billion people.
We are aiming to enter the insulin market with Biosimilars – a follow-on medicines of biologic when the patent has expired. We want to increase access by creating competition, making the medicines more affordable and thus more accessible. It’s time to capture the insulin market and make it affordable for everyone!
To ensure that nobody is without the opportunity to access and afford insulin, we challenge you to re-imagine access to insulins and come up with community and partner oriented business models that enable access for everyone.
Why? Because we are unwilling to accept that at least 400 million people worldwide cannot access essential health services and more than 2 billion cannot afford to buy the medicines they need. Let’s find a way to give access to everyone!
To help you understand how we re-imagine, we can imagine multiple ways to create sustainable collective action:
- Innovative ways to differentiate prices to support patients with no insurance, or to support patients who prefer not to use their insurance.
- “Buy 1 dose and support another patient” model
- An “air miles” style points and rewards program
- A flat rate subscription model with a certain % used to fund patients in need
- Use technology and devices to best improve access to insulins and medical information
- What can you imagine?
That’s why we challenge you to re-imagine diabetes care and co-create with us the insulin revolution by giving sustainable access to insulin to everyone in need. How can we…
… get in direct contact with our patients?
… get them to help and support each other?
… be competitive to existing insulin treatments?
… create a business model that works for all involved parties?
… package insulin so it can be delivered from any pump or pen?
… provide value through connected insulin injection devices?
… make the insulin provision process sustainable or even recyclable?